# Ark Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ark-biotech

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.ark-biotech.com
- Total disclosed funding: $2.5M
- Latest round: Seed (Dec 10, 2021)
- Investors on record: 2

## About

Ark Biotech Inc. develops advanced simulation software for bioprocess management, enhancing efficiency in biopharmaceutical development. Their innovative solutions accelerate the testing and optimization of cell culture processes, enabling rapid decision-making and improved outcomes.Founded in 2021 in New York, US, Ark Biotech Inc. specializes in high-fidelity simulation software for bioprocess management. The company successfully secured USD 6.000 mn during its Seed funding round in April 2022, raising a total of USD 6.000 mn. With a current valuation of USD 26.893 mn, Ark has completed 2 deals to date.Ark provides high-fidelity simulation software designed to optimize bioprocess management across various stages of development, from early-stage process development to commercial manufacturing. The software enables users to simulate thousands of experiments in parallel, improving decision-making and accelerating time to market. It allows scientists to test hypotheses in silico, minimizing the need for physical experiments, thus enhancing process robustness and efficiency. Ark's offerings are tailored for professionals in biopharmaceutical development, specifically targeting cell culture processes to predict and analyze performance metrics such as titer, viability, and metabolic indicators. The company primarily serves markets in North America, Europe, and parts of Asia, catering to clients in the biotechnology and pharmaceutical industries who require advanced bioprocessing solutions.Ark's revenue model is structured around software subscriptions and partnerships, facilitating B2B transactions with clients in the biopharmaceutical sector. Clients pay for access to Ark's advanced simulation tools, which provide services such as model calibration, process optimization, and ongoing updates to ensure compliance with the latest security standards. The company’s flagship offerings, which include a comprehensive library of bioreactor models and customizable simulation options, are accessed through tiered subscription plans that cater to varying user needs and organizational scales. Revenue is generated by providing customers with a secure, tailored simulation environment while maintaining strict data security protocols.Ark Biotech Inc. plans to leverage its recent funding of USD 6.000 mn raised in April 2022 to enhance its product offerings and accelerate market expansion. The company is focused on developing new simulation tools aimed at improving bioprocess strategies. Furthermore, Ark aims to penetrate additional markets in Europe and Asia by the end of 2023, thereby broadening its global footprint and customer base.

## Funding rounds

- Seed, Dec 10, 2021, $2.5M — Primary Venture Partners, HCVC

## Investors

- Primary Venture Partners (https://capitalatlas.ai/funds/primary-venture-partners) — Seed
- HCVC (https://capitalatlas.ai/funds/hcvc) — Seed